2.1 The regulatory asymmetry: your constraints do not bind your describers
Pharmaceutical communication is governed by promotional regulation: claims must match the approved label, fair balance must be maintained, and off-label discussion is prohibited. General-purpose AI systems observe none of these constraints. They will happily synthesize off-label uses, blend investigational data with approved indications, and present pipeline compounds as available therapies — while the manufacturer, the only actor with complete and current knowledge of the clinical truth, is the actor most constrained in correcting the record.14,19 This asymmetry means the manufacturer's best defence is not rebuttal but pre-emption: making the approved, accurate, current version of the truth the easiest version for machines to find and reuse.
2.2 Dual audiences with asymmetric stakes
The same model answers the oncologist and the patient, but the failure modes differ. For clinicians, the dominant risks are version currency (obsolete label details), precision loss (rounded or unqualified efficacy figures), and subgroup conflation. For patients, the dominant risks are comprehension failures, missing safety context, and tone — an answer that is technically accurate but frightening or falsely reassuring. Field audits show general-purpose models frequently blur audience boundaries, citing patient-facing sources in clinical answers and vice versa when content is not explicitly audience-labeled.19
2.3 A legacy content estate engineered for the wrong reader
Decades of pharmaceutical digital investment produced an estate optimized for human eyes and legal review: image-rich PDFs, conference posters, slide decks, gated portals, video, and long promotional prose. Retrieval systems cannot see most of it. Image-locked documents are effectively invisible; gated content is categorically invisible; and marketing prose — superlatives without numbers — offers the retrieval layer nothing to anchor on.19,24 Industry estimates suggest a majority of traditional pharmaceutical web content is poorly parsed or entirely ignored by modern retrieval-augmented generation systems, a finding replicated in the GEOMed360 field audits.19
2.4 Hallucination risk concentrates where content is scarce
Large language models fill gaps. Reviews of documented failure cases in pharmaceutical contexts record fabricated clinical trials, invented mechanisms of action, and fictitious citations delivered with full fluency.14 Foundational work on medical hallucination shows the risk is highest precisely where authoritative, machine-readable content is thinnest — newly approved products, updated labels, special populations, and negative findings (what a drug does not do) that no one bothered to state explicitly.14,15 Retrieval grounding is the strongest known mitigation: on a standard biomedical question-answering benchmark, retrieval-augmented generation raised accuracy from 57.9 percent to 86.3 percent versus the same model unaided — but retrieval can only ground on content that exists in retrievable form.15
The cost of inaction is a compounding error term
AI-generated answers are not static. Each model refresh, each newly indexed third-party page, and each user interaction subtly reshapes what the machines say about a therapy. Errors that enter the ecosystem early — an outdated label figure, a mislabeled subgroup result, a class-effect assumption — propagate across derivative sources and are then reinforced by the very corroboration heuristics models use to establish confidence.14,19
Field observation confirms the compounding: in one audit, a dosing error originating in a single non-peer-reviewed chemistry aggregator was reproduced by multiple general-purpose models months later, because the error had been syndicated across several derivative sites that the models treated as independent confirmation.19